Search Results

After twenty years as one of the first personalized oncology companies, Indivumed announced its evolution into Indivumed Therapeutics after the acquisition of Indivumed Services GmbH and its CRO service offerings by Crown Bioscience.

Indivumed Services GmbH, a Crown Bioscience company, announced that its Hamburg site received laboratory accreditation from the College of American Pathologists.

Crown Bioscience, a global contract research organization and JSR Life Sciences company, announced that it has completed its acquisition of the IndivuServ business unit of Indivumed GmbH on March 31, 2023.

Crown Bioscience , a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH.

Indivumed GmbH (“Indivumed”) announced today the founding of Ix Therapeutics GmbH (“Ix Therapeutics”), a joint venture with Xlife Sciences AG (“Xlife Sciences”), which marks Indivumed’s expansion into target discovery and early cancer drug development

Indivumed GmbH announced the launch of nRavelTM, a unique AI discovery platform for oncology and precision medicine.

Ultivue and Indivumed today announced that the two companies have entered into a collaborative partnership to further accelerate research and drug development in the area of personalized oncology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005281/en/ The deal links Indivumed’s vast array of standardized and fully c

VERAXA Biotech GmbH, Heidelberg, and Indivumed GmbH, Hamburg, announced today their agreement to jointly discover modulatory and functional antibodies against several targets that are relevant for colorectal cancer.